News & Analysis
- Data & Tools
- Login | Register
David is a Partner in the Life Sciences group and has a diverse practice, working with therapeutic proteins, modified nucleic acids and traditional small molecules. He frequently handles platform technology cases, from drafting provisionals to worldwide prosecution, and from divisional strategy to post-grant opposition. He has particular experience helping start-up and early stage companies build their IP strategy, with recent successes for Tricida, Modis Therapeutics, Ambrx and Frequency Therapeutics. David’s advice is built on over a decade supporting both start-ups and more established players such as Ionis Pharmaceutics, Incyte, Acorda and Sanofi.
Get unlimited access to all IAM content